There are indications of a 94% reduction in symptoms of COVID-19 among 600,000 people who received two doses of Pfizer vaccine in the largest Israeli study to date.
According to a Reuters report, “Health Maintenance Organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was 92% less likely to develop a severe disease than the virus. “
READ: COVID-19: Evidence suggests new variants could challenge vaccines
What are they saying
In words Ran Balicer, Clalit’s chief innovation officer,,
- “It unequivocally shows that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as found in a clinical study.
- “The data show that the Pfizer vaccine, which was developed in partnership with Germany’s BioNTech, is even more effective two weeks or more after the second shot.”
READ: Covid-19: Travel agencies recorded sales loss of 46.9% in 2020 – NANTA
According to Reuters, “Researchers from the Weizmann Institute of Science, who collected national data, said on Sunday that for the first time a sharp drop in hospitalizations and serious illnesses identified earlier was seen among the first age group to be vaccinated – aged 60 or older in those older than 55 years.”
What you should know
- It is important to note that hospitalizations and serious illnesses were still growing in the younger groups who started vaccination weeks later.
- Israel is implementing a rapid introduction of the vaccine and its database offers insight into the effectiveness of the vaccine and at what point countries could acquire herd immunity.
- To date, Israel has reported a total of 724,000 cases, 664,000 recoveries and 5,388 deaths.